亚太药业：公司控股股东将由富邦集团变更为星浩控股

Core Viewpoint - Asia-Pacific Pharmaceutical (亚太药业) announced a share transfer agreement involving its controlling shareholder, Ningbo Fubon Group (富邦集团), which will transfer 14.61% of its shares to Zhejiang Xinghao Holdings (星浩控股) for a total of 900 million yuan at a price of 8.26 yuan per share, changing the controlling shareholder and actual controller to Qiu Zhongxun [1][2] Group 1 - The share transfer involves a total of 108,945,566 shares, which represents 14.61% of Asia-Pacific Pharmaceutical's total shares [1] - The transaction will be executed in five installments, with performance commitments from the transferor to ensure that the company's main business revenue in 2025 will not be less than 360 million yuan, and the net profit loss will not exceed 70 million yuan [1] - If the performance commitments are not met, the transferor will compensate the acquirer as per the agreement [1] Group 2 - Xinghao Holdings will directly acquire 60,525,314 shares (8.12% of total shares), while its action-in-concert party, Xingchen Investment (星宸投资), will acquire 48,420,252 shares (6.49% of total shares) [2] - To ensure stable control, Xingchen Investment will delegate all voting rights of its shares to Xinghao Holdings [2] - Asia-Pacific Pharmaceutical also plans to raise up to 700 million yuan through a private placement to Xinghao Holdings for new drug research and development, with a share price of 5.11 yuan and a maximum issuance of 136,986,301 shares [2] Group 3 - The company currently focuses on chemical generic drugs and faces performance pressure due to national centralized procurement and consistency evaluation policies, indicating a pressing need for business transformation [2] - The fundraising project is a key step in implementing the company's "combination of imitation and innovation, innovation-driven" development strategy, aimed at optimizing product structure and enhancing core competitiveness and profitability [2] - Xinghao Holdings was established on July 3, 2025, and its actual controller, Qiu Zhongxun, also controls the domestic pharmaceutical e-commerce platform "Yao Dou Technology" (药兜科技), which collaborates with over 4,000 upstream pharmaceutical companies and approximately 650,000 downstream commercial and terminal customers [2]